8-K: Recursion Pharmaceuticals Registers Resale of 3.5 Million Shares Issued to Tempus Labs

Recursion Pharmaceuticals has filed a prospectus supplement to register for resale approximately 3.5 million shares of its Class A common stock, which were previously issued to Tempus Labs as payment for a license fee.

Summary

• Recursion Pharmaceuticals filed a prospectus supplement on December 17, 2024, to register for resale 3,498,393 shares of its Class A common stock.
• These shares were initially issued to Tempus Labs as payment for the 2024 annual license fee under a Master Agreement between the two companies.
• The resale of these shares is being made under an exemption from registration under the Securities Act of 1933.
• The legal opinion regarding the validity of these shares has been provided by Wilson Sonsini Goodrich & Rosati, P.C.

Sentiment

Score: 6

Explanation: The document is a routine filing related to a prior agreement. It is neither particularly positive nor negative, but rather a procedural step.

Positives

• The registration of the resale shares allows Tempus Labs to potentially liquidate their holdings.
• The legal opinion from Wilson Sonsini Goodrich & Rosati, P.C. confirms the validity of the shares.

Risks

• The resale of a large number of shares could potentially put downward pressure on Recursion's stock price.
• The market's reaction to the resale is uncertain.

Future Outlook

The document does not contain any specific forward-looking statements or guidance from the company.

Industry Context

This announcement is related to the ongoing business relationship between Recursion Pharmaceuticals and Tempus Labs, specifically regarding the payment of licensing fees through the issuance of stock. It reflects a common practice in the biotech industry where companies use equity to settle obligations.

Comparison to Industry Standards

• The use of stock to pay for licensing fees is a common practice in the biotechnology industry, particularly for companies that are still in the development phase.
• Many biotech companies, such as Moderna and BioNTech, have used similar methods to manage their cash flow and strategic partnerships.
• The size of the share issuance, approximately 3.5 million shares, is not unusual for a company of Recursion's size and stage of development.

Related Party Transactions

• The issuance of shares to Tempus Labs for the annual license fee is a related party transaction.

Stakeholder Impact

• Shareholders may experience some volatility in the stock price due to the potential resale of a large number of shares.
• Tempus Labs will be able to monetize their holdings in Recursion.

Next Steps

• The resale of the registered shares by Tempus Labs is expected to occur over time.
• Recursion will continue to operate under the terms of the Master Agreement with Tempus.

Key Dates

Keywords

Recursion Pharmaceuticals, Tempus Labs, Resale Shares, Class A Common Stock, Prospectus Supplement, License Fee, Securities Act of 1933, Wilson Sonsini Goodrich & Rosati